MERZ-AESTHETICS
21.3.2024 09:01:28 CET | Business Wire | Press release
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, is presenting new data for its product portfolio in addition to perspectives on medical aesthetics trends at the 2024 Aesthetic and Anti-Aging Medicine World Congress. AMWC is a leading global scientific conference specializing in aesthetic and anti-aging medicine. Participants can attend live in Monaco or tune in virtually beginning March 27 through March 29, 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321775430/en/
Merz Aesthetics’ programming includes a sponsored symposium on March 28 from 14:00 - 16:00 CET, Beauty Without Borders: Aesthetics Across Continents, moderated by Dr. Sabrina Fabi, featuring commentary from Dr. Kate Goldie, Dr. Siew Tuck Wah, Dr. Rolf Bartsch and Dr. Rossana Vasconcelos. During the session, the group will discuss the multifaceted landscape of beauty and aging around the world, the nuances and variances of aging concerns among different patient populations and the recommended techniques and products.
“Each year, AMWC allows us the opportunity to connect and collaborate with peers from around the world and provides a forum to showcase our research and advancements in medical aesthetics,” said Terri Phillips, MD, Chief Medical Affairs Officer, Merz Aesthetics. “We’re excited to engage in scientific exchange, foster new connections and discuss innovations within our portfolio, in addition to sharing insights from the evolving field of regenerative aesthetics.”
“At Merz Aesthetics, we aim to provide the best experience possible for our health care professionals and their patients,” said Gonzalo Mibelli, President, EMEA, Merz Aesthetics. “I’m looking forward to presenting our latest data and honoring the commitment we’ve made to our customers to meet their evolving needs.”
In addition to the symposium, Merz Aesthetics is presenting five e-posters for the first time. The abstracts will be available for viewing on-site throughout the congress and displayed on the virtual e-poster platform with detailed abstracts. Following are the highlighted e-posters:
- Long-term Duration and Safety of CaHA(+)-CMC for the Treatment of Jawline – Jeremy B. Green, MD, Roberta Del Campo, MD, Alan J. Durkin, MD, David K. Funt, MD, Nicole Nasrallah, MS, Keith Martinez, PhD, Amir Moradi, MD
- Tissue Integration of Hyaluronic Acid-Containing Dermal Fillers: Automated Approach Using a Human Skin Model Under Optimal Tension – Kay Marquardt, PhD, Christian Hartmann, PhD, Michael Conneely, PhD, Robyn Hickerson, PhD, Kristina Riegel, PhD, Thomas Hengl, PhD
- Stimulation of Elastin Neogenesis by Micro-Focused Ultrasound (MFU-V) – Kay Marquardt, PhD, Christian Hartmann, PhD, Flora Wegener, PhD, Nils Warfving, PhD, Kristina Riegel, PhD, Thomas Hengl, PhD
- Consensus Agreements on Regenerative Aesthetics: Terminology, Goals, and Strategies – Dr. Kate Goldie, Dr. Greg Chernoff, Dr. Niamh Corduff, Dr. Owen Davies, Dr. Jani van Loghem, Dr. Bianca Viscomi
- Micro-focused Ultrasound with Visualization and Aesthetic Outcomes: A Systematic Review and Meta-analysis of Clinical Studies – Dr. Sabrina Guillen Fabi, Dr. Gabriela Casabona, Dr. Tatjana Pavicic, Dr. Julia Sevi, Dr. Julieta Spada, Dr. Vasanop Vachiramon, Dr. Rossana Vasconcelos, Dr. Siew Tuck Wah
Merz Aesthetics will be located at Booth J1 on Level 1.
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.
Copyright © 2024 Merz Aesthetics GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321775430/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yamaha to Acquire Disguise, Expanding Its Capabilities in Integrated Audio, Video, Lighting and Media13.11.2026 08:00:00 CET | Press release
Acquisition combines Yamaha’s audio expertise with Disguise’s software and media server technologies Yamaha Corporation today announced an agreement to acquire Disguise Technologies Limited (“Disguise”), a London-based provider of software and media server technologies for live and immersive experiences. Yamaha will acquire the company by purchasing all shares in its parent, Butterfly Topco Limited. The acquisition will expand Yamaha’s capabilities beyond audio into integrated audio, video, lighting and media solutions, in line with its strategy to expand beyond hardware into software and services. By combining Yamaha’s audio expertise and global reach with Disguise’s software, technologies and worldwide partner network, the companies will be better positioned to deliver immersive experiences across live entertainment, sports and other venues. Disguise’s technology powers live and immersive experiences worldwide, including tours by Beyoncé and Taylor Swift and venues such as New York’s
Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane® Shaype™ for Both Chin and Its First Jawline Indication13.11.2026 07:00:00 CET | Press release
Restylane Shaype is now approved in Mexico for temporary augmentation in the chin area and improvement of jawline definition,1 with launch anticipated in H1 2027 Already approved across various markets globally for the chin area,2 this marks Restylane Shaype’s first approval for the jawline worldwide1 The first-and-only shaper on the hyaluronic acid (HA) market, Restylane Shaype features the firmest HA gel available and is powered by proprietary NASHA HD™ technology, developed to build and shape on bone for instant, natural-looking contour and definition3-6 The approval reinforces Galderma's commitment to advancing innovation in the HA category, enabling the company to meet diverse patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that Restylane Shaype has been approved for temporary augmentation in the chin area and improvement of jawline definition in Mexico.1 This is the product’s first approval globally for the jawline, and further expan
vVARDIS Announces Pricing of Initial Public Offering13.11.2026 06:02:00 CET | Press release
vVARDIS Holding AG (“vVARDIS”), a Swiss healthcare company operating in the dental med-tech sector, today announced the pricing of its initial public offering of 9,722,223 Class A ordinary shares at a public offering price of $18.00 per share. In connection with the offering, vVARDIS has granted the underwriters a 30-day option to purchase up to an additional 1,458,333 Class A ordinary shares at the initial public offering price to cover over-allotments. The Class A ordinary shares are expected to begin trading on the New York Stock Exchange on November 13, 2026 under the symbol “VVVV.” The closing of the offering is expected to occur on or about November 16, 2026 subject to the satisfaction of customary closing conditions. Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint bookrunning managers for the offering, with William Blair, UBS Investment Bank and Deutsche Bank Securities acting as bookrunners. A registration statement on Form F-1 relating to the offering has been file
Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*12.11.2026 23:07:00 CET | Press release
The multi-level takeover includes a Throne Room, interactive photo opportunities, special lighting, and more The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience
Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 18:09:00 CET | Press release
Veristat’s InStat™ delivers submission-ready tables, listings, and figures (TLFs) in one week using validated statistical engines, shortening the critical path from database lock to submission VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom